Authors' objectives: Hodgkin lymphoma is a cancer of the lymphatic system – part of the body's immune system. In Hodgkin lymphoma, blood cells called lymphocytes become abnormal, increase in number and collect in the lymph nodes (glands) and other organs. Nivolumab is a new antibody drug for the treatment of Hodgkin lymphoma, and is delivered straight into the bloodstream via a drip. Some studies have suggested nivolumab may be helpful for people whose first treatment has failed and whose disease has spread despite treatment with a bone marrow transplant. Nivolumab is currently being studied to see how well it works and whether it is safe to use in people with Hodgkin lymphoma. If nivolumab is licensed for use in the UK, it could be a new treatment option for this patient group that may improve survival and quality of life when current treatments have not worked.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/nivolumab-opdivo-for-hodgkin-lymphoma-in-brentuximab-naive-patients-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)